KMT2A and neoplasm: In their work, Mouti et al. demonstrated that using the KMT2A-WDR5 inhibitor to target the protein subcomplex in pancreatic CSCs reduced the cells’ ability to self-renew, their survival, and their ability to cause tumours in vivo [158].